1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
JW Pharmaceutical Corporation

JW Pharmaceutical Corporation

001065.KS
JW Pharmaceutical CorporationKR flagKorea Exchange
19,900.00
KRW
- -
- -
351.07BMarket Cap

Total Valuation

JW Pharmaceutical Corporation carries a market capitalization of 351.07B, placing it among publicly traded companies globally. Its enterprise value stands at -8.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap351.07B
Enterprise Value-8.16B

Share Statistics

JW Pharmaceutical Corporation currently has 22.55M shares outstanding.

Shares Outstanding22.55M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

On an enterprise value basis, JW Pharmaceutical Corporation trades at an EV/EBITDA multiple of 0.24 and an EV/FCF ratio of 0.25. The EV/Sales ratio of 0.03 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.24 provides insight into valuation relative to core operating earnings.

EV / Sales0.03
EV / EBITDA0.24
EV / EBIT0.24
EV / FCF0.25

Financial Position

JW Pharmaceutical Corporation maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Current Ratio1.46
Quick Ratio0.31
Debt / Equity14.18
Debt / EBITDA0.51
Interest CoverageN/A

Financial Efficiency

JW Pharmaceutical Corporation posts a return on equity of 27.87 and a return on invested capital of 18.82.

Return on Equity (ROE)27.87
Return on Assets (ROA)11.60
Return on Invested Capital (ROIC)18.82
Return on Capital Employed (ROCE)21.83
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.52

Taxes

Over the trailing twelve months, JW Pharmaceutical Corporation has paid 29.66B in income taxes, reflecting an effective tax rate of 29.31.

Income Tax29.66B
Effective Tax Rate29.31

Stock Price Statistics

JW Pharmaceutical Corporation's stock has declined approximately -33.33333% over the past 52 weeks. The 50-day moving average sits at 23,433.60, while the 200-day moving average is 26,804.40.

Beta (5Y)N/A
52-Week Price Change-33.33333%
50-Day Moving Average23,433.60
200-Day Moving Average26,804.40
Average Volume (20 Days)N/A

Income Statement

EBITDA reached 106.03B, while operating income came in at 106.03B.

Revenue789.95B
Gross Profit373.59B
Operating Income106.03B
Pretax Income101.18B
Net Income71.52B
EBITDA106.03B
EBIT106.03B
Earnings Per Share (EPS)N/A

Balance Sheet

JW Pharmaceutical Corporation holds 66.32B in cash and equivalents against 54.12B in total debt, resulting in a net debt position of 11.55B. Total book value stands at 284.56B, with working capital of 97.54B providing operational flexibility.

Cash & Cash Equivalents66.32B
Total Debt54.12B
Net Debt11.55B
Equity (Book Value)284.56B
Book Value Per ShareN/A
Working Capital97.54B

Cash Flow

JW Pharmaceutical Corporation produced 85.32B in operating cash flow over the past twelve months.

Operating Cash Flow85.32B
Capital Expenditures-34.43B
Free Cash Flow50.89B
FCF Per ShareN/A

Margins

JW Pharmaceutical Corporation operates with a gross margin of 47.29, reflecting its pricing power and cost economics. The operating margin of 13.42 and net profit margin of 9.05 provide insight into operational efficiency.

Gross Margin47.29
Operating Margin13.42
Pretax Margin12.81
Profit Margin9.05
EBITDA Margin13.42

Stock Splits

JW Pharmaceutical Corporation's most recent stock split took place on December 27, 2023 with a 50:51 split ratio.

Last Split Date12/27/2023
Split Ratio50:51

Scores

JW Pharmaceutical Corporation posts an Altman Z-Score of 2.84, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.84